Latest Bupropion/naltrexone Stories
- Contrave® net sales total $11.5 million in the first full quarter of launch SAN DIEGO, May 8, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc.
NEW YORK, April 15, 2015 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased Orexigen Therapeutics, Inc.
NEW YORK, March 6, 2015 /PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Orexigen
- Contrave® net sales total $6.5 million in first 10 weeks of launch SAN DIEGO, Feb. 25, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc.
SAN DIEGO, Feb. 9, 2015 /PRNewswire/ -- Orexigen Therapeutics, Inc.
LA JOLLA, Calif., Dec.
SAN DIEGO, Nov. 10, 2014 /PRNewswire/ -- Orexigen(®) Therapeutics, Inc.
The FDA has approved the weight loss pill Contrave, a medication that will be used to treat obese adults in conjunction with a controlled diet and exercise.
- Patent Protection for NB32 for Treating Insulin Resistance - SAN DIEGO, Sept. 2, 2014 /PRNewswire/ -- Orexigen Therapeutics, Inc. (Nasdaq: OREX) today announced that the U.S.
SAN DIEGO, Feb. 6, 2014 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX) today announced that management will be presenting at two upcoming investor conferences.
- The parings of haberdine; also, any kind of fragments.